Thirty years ago this October, Merck & Co. vowed that it would immediately begin distributing the drug free of charge, to any country that requested it, “for as long as needed.” It was the final piece of the puzzle: an effective drug for a tragic and completely preventable disease. And we all lived happily ever after. Only… we didn’t.

Quick Read

It’s worth noting that Medicaid expansion helps pay for opioid addiction treatment, said Brendan Saloner of Johns Hopkins Bloomberg School of Public Health. Medicaid expansion covers costs treatments like detoxification, outpatient treatment, and treatment for masked health conditions

Quick Read

Researchers at the University of Maryland School of Medicine were shocked to find that nearly half of all medical care in the United States is delivered at hospital emergency departments

Quick Read

Adam Gaffney and our Zackary Berger write, “Single payer bills signal a new era in American healthcare politics”

Quick Read

Total costs of Kymriah and the 21 similar drugs in development — known as CAR T-cell therapies — will be far higher than many have imagined, reaching $1 million or more per patient, according to leading cancer experts. The next CAR T-cell drug could be approved as soon as November.

Quick Read

A federal judge in Texas invalidated four key patents for the dry-eye treatment Restasis on Monday, dealing a blow to its manufacturer, Allergan, which had sought to protect its patents by transferring them to a Native American tribe

Quick Read

Who will pay for it? And how?

Quick Read

“At first it’s cool, and then you realize, I’m filling some drugs that are for some pretty serious health problems as well. And these are the people that are running the country,” Pharmacist Mike Kim said, listing treatments for conditions like diabetes and Alzheimer’s. “It makes you kind of sit back and say, ‘Wow, they’re making the highest laws of the land and they might not even remember what happened yesterday.’”

Quick Read